Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
55 Leser
Artikel bewerten:
(0)

Merge eMed to Showcase Innovative Imaging Solutions at The American College of Radiology National Conference on Breast Cancer (NCBC)


MILWAUKEE, April 29 /PRNewswire-FirstCall/ -- Merge eMed, a Merge Healthcare company (Nasdaq: MRGE; TSX: MRG) and a leading medical imaging software and services company, today announced that it will showcase Cedara I-ReadMammo(TM) digital mammography workstation software and Cedara B-CAD, a solution designed to assist radiologists in the analysis of breast lesions using ultrasound images, at ACR's National Conference on Breast Cancer, April 29 - 30, in San Diego, CA.

(Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030430/MRGELOGO )

Cedara I-ReadMammo is a multi modality, vendor-neutral mammography workstation software solution, designed to help organizations streamline breast imaging workflow and reduce costs in adopting digital mammography. Another innovative solution that will be featured is Cedara B-CAD, which is uniquely positioned to reduce the quantity of time required by a radiologist to analyze and report the findings of breast ultrasound images. This timesaving application provides tools for automatic image analysis, segmentation, and classification.

"The value proposition for our customers is a short ROI, with even lower volume sites having a payback within one year," said Beth Frost-Johnson, Merge Healthcare Senior Vice-President, Marketing. "This is another example of ways in which Merge eMed works as a business partner with its customers, creating solutions that add to the financial and clinical health of their businesses. We are pleased to create and own our RIS/PACS and Clinical Applications that deliver solid ROI's for our customers."

Cedara I-ReadMammo and B-CAD will be shown in the Merge eMed booth, #512. For additional information, visit Merge eMed's special mammography site at http://www.ireadmammo.com/, or to learn more about Merge eMed's RIS, PACS, RIS/PACS and other clinical applications, go to http://www.merge-emed.com/.

Merge Healthcare is a market leader in the development and delivery of medical imaging and information management software and services. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at http://www.merge.com/.

Merge eMed, a Merge Healthcare company, is focused on accelerating productivity for radiology departments and specialty practices, imaging centers and hospitals. By combining sophisticated RIS, PACS, advanced visualization and clinical imaging applications, Merge eMed delivers integrated end-to-end software solutions and professional services that are transforming the way our customers interact with referring physicians, manage their workflow, position their businesses in their markets and deliver imaging and information services to their customers. For additional information, visit our website at http://www.merge-emed.com/.

Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words: guidance, believes, intends, anticipates, expects, and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements based on a number of factors, including, but not limited to, risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, unexpected outcomes to any pending or future litigation, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect any future events or circumstances.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030430/MRGELOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2006 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.